Brief: Hutchmed (China) Says FDA Orphan Drug Designation For Sovleplenib In Primary Immune Thrombocytopenia
BRIEF-Hutchmed (China) Says FDA Orphan Drug Designation For Sovleplenib In Primary Immune Thrombocytopenia Oct 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SOVLEPLENIB IN PRIMARY IMMUNE THROMBOCYTOPENIA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))